← Leaderboards
Pengbo Zhou
Weill Medical Coll Of Cornell Univ
$14,509,570
Attributed
$17,187,513
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,187,513 · 12
By mechanism
R01$15,272,452 · 7
R33$1,001,887 · 1
R21$338,500 · 2
R56$328,556 · 1
R41$246,118 · 1
Top collaborators
- Sandra Shin5 shared
- Xiaojing Ma3 shared
- Christopher E Barbieri2 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Marcus Dasilva Goncalves$8,791,437
- Sandra Shin$1,000,502
Others in their field
Top investigators on “Biochemical”
- Michael W Weiner · Northern California Institute Res &Educ$74,211,055
- Bruce W Stillman · Cold Spring Harbor Laboratory$47,787,987
- John Damon Chodera · Sloan-Kettering Inst Can Research$47,159,667
- Nanduri R Prabhakar · Case Western Reserve University$46,495,566
- Richard C Boucher · University Of North Carolina Chapel Hill$44,019,683
- Peter D Karp · Sri International$43,901,053
Research focus
BiochemicalUbiquitinIn VivoTumorUbiquitin LigaseBasePlayRegulationUbiquitinationMalignant NeoplasmsMouse ModelComplexResistanceGenesMediatingCellsMolecularPathway InteractionsHandProteolysisMutantTumorigenesisIn VitroEvent
Grant awards (42)
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer$710,980
R01 · FY2025 · CA · contact PI
UBR5's mechanisms of action in tumorigenesis and immunoregulation$655,228
R01 · FY2025 · CA
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer$710,980
R01 · FY2024 · CA · contact PI
UBR5's mechanisms of action in tumorigenesis and immunoregulation$622,468
R01 · FY2024 · CA
UBR5's mechanisms of action in tumorigenesis and immunoregulation$655,228
R01 · FY2023 · CA
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis$482,534
R01 · FY2022 · CA · contact PI
Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs$246,118
R41 · FY2022 · CA · contact PI
Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis$517,885
R01 · FY2021 · CA · contact PI
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis$485,348
R01 · FY2021 · CA · contact PI
Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis$512,266
R01 · FY2020 · CA · contact PI
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis$506,451
R01 · FY2020 · CA · contact PI
Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis$561,496
R01 · FY2019 · CA · contact PI
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis$484,436
R01 · FY2019 · CA · contact PI
Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis$609,229
R01 · FY2018 · CA · contact PI
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis$489,569
R01 · FY2018 · CA · contact PI
Harnessing the CRL4 ubiquitin ligase for antagonizing colorectal carcinogenesis$513,850
R01 · FY2017 · CA · contact PI
Tumorigenic Role of the CUL4A Ubiquitin Ligase$403,562
R01 · FY2015 · CA · contact PI
Tumorigenic Role of the CUL4A Ubiquitin Ligase$393,337
R01 · FY2014 · CA · contact PI
Tumorigenic Role of the CUL4A Ubiquitin Ligase$383,037
R01 · FY2013 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$301,361
R01 · FY2013 · CA · contact PI
Tumorigenic Role of the CUL4A Ubiquitin Ligase$409,503
R01 · FY2012 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$320,596
R01 · FY2012 · CA · contact PI
Tumorigenic Role of the CUL4A Ubiquitin Ligase$411,564
R01 · FY2011 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$320,596
R01 · FY2011 · CA · contact PI
Development of high throughput assays to identify small molecule inhibitors of th$169,000
R21 · FY2011 · NS · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$330,512
R01 · FY2010 · CA · contact PI
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis$290,571
R01 · FY2010 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$330,349
R01 · FY2009 · CA · contact PI
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis$290,571
R01 · FY2009 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$328,556
R56 · FY2008 · CA · contact PI
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis$290,571
R01 · FY2008 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$321,835
R01 · FY2007 · CA · contact PI
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis$290,571
R01 · FY2007 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$331,447
R01 · FY2006 · CA · contact PI
Ubiquitin-Proteolytic Control of HOXA9 in Leukemogenesis$316,249
R01 · FY2006 · CA · contact PI
Regulation of Nucleotide Excision Repair by Proteolysis$339,424
R01 · FY2005 · CA
Protein Knockout Technology/Molecular Analysis of Cancer$376,720
R33 · FY2004 · CA
Regulation of Nucleotide Excision Repair by Proteolysis$339,424
R01 · FY2004 · CA
Regulation of Nucleotide Excision Repair by Proteolysis$339,424
R01 · FY2003 · CA
Protein Knockout Technology/Molecular Analysis of Cancer$317,202
R33 · FY2003 · CA
Protein Knockout Technology/Molecular Analysis of Cancer$307,965
R33 · FY2002 · CA
Protein Knockout Technology/Molecular Analysis of Cancer$169,500
R21 · FY2001 · CA